SILAC-based Proteomics Analysis on AML Cell Line with Transient Low-Dose Decitabine Treatment
碩士 === 國立臺灣大學 === 毒理學研究所 === 106 === Acute myeloid leukemia (AML) is an aggressive type of white blood cell cancer with most patients being beyond 60 years of age. These elderly patients are often present with various comorbidities that make them unsuitable for harsh conventional chemotherapy or cur...
Main Authors: | Giovanni Audrey Oswita, 胡斯萍 |
---|---|
Other Authors: | Hsing-Chen Tsai |
Format: | Others |
Language: | en_US |
Published: |
2018
|
Online Access: | http://ndltd.ncl.edu.tw/handle/e3m5sa |
Similar Items
-
Therapeutic effect of TRC105 and decitabine combination in AML xenografts
by: June Baik, et al.
Published: (2020-10-01) -
Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
by: Ye X, et al.
Published: (2017-11-01) -
Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
by: Tremblay G, et al.
Published: (2019-09-01) -
Hepatic SILAC proteomic data from PANDER transgenic model
by: Mark G. Athanason, et al.
Published: (2016-12-01) -
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
by: Lia Gore, et al.
Published: (2017-10-01)